Lv11
30 积分 2025-09-23 加入
A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation
1小时前
待确认
HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
1小时前
已完结
Exploring molecular interactions of potential inhibitors against the spleen tyrosine kinase implicated in autoimmune disorders via virtual screening and molecular dynamics simulations
3个月前
已完结
Structure-based Drugs Design Studies on Spleen Tyrosine Kinase Inhibitors
3个月前
已完结
Integrated Artificial Intelligence and Physics-Based Methods for the De Novo Design of Spleen Tyrosine Kinase (SYK) Inhibitors
3个月前
已完结
皖公网安备34019202002308
